Project 1:Diabetes, RAGE/DIAPH1 and Myocardial Infarction

项目1:糖尿病、RAGE/DIAPH1与心肌梗死

基本信息

项目摘要

Project Summary: Project 1 Cardiovascular disease (CVD), that include increased sensitivity of diabetic (DM) myocardium to ischemic injury, represents the major cause of morbidity and mortality in patients with diabetes. We have uncovered key roles for the receptor for advanced glycation end products (RAGE -gene symbol Ager) in DM and myocardial ischemia/reperfusion (I/R), as global deletion of Ager attenuated myocardial injury, reduced oxidative stress, increased functional recovery and preservation of ATP compared to wild-type (WT) littermates. Mechanisms by which Ager deletion confers metabolic and functional protection in DM and non-DM (NDM) I/R hearts will be the focus of this project. Our program discovered that the RAGE cytoplasmic domain interacts with diaphanous-1 (DIAPH1), an effector of RhoGTPases, is essential for RAGE ligand-mediated cellular migration and activation of cdc42/rac-1. Our recent studies demonstrated that DIAPH1 is expressed in cardiomyocytes (CMs) and that I/R increases expression of Diaph1. Key preliminary data reveal reduced infarct size and improved functional recovery after I/R in (a) WT mice transplanted with bone marrow derived cells from Ager null mice,(b) mice with CM specific deletion of Ager/Diaph1, and (c) WT mice hearts perfused with conditioned media from Ager null or Diaph1 null macrophages (MΦs). Novel findings in CMs and MΦs reveal that DIAPH1 interacts with mitochondrial GTPase mitofusin2 (MFN2) and augments MFN2's tethering of sarcoplasmic reticulum (SR) to mitochondria (mito) and consequently mito calcium regulation. Importantly, our data shows that high glucose, ligands of RAGE, and RAGE-DIAPH1 interaction further augments DIAPH1-MFN2 driven mito-SR tethering. Taken together, these data led us to hypothesize that RAGE/DIAPH1 mediates DIAPH1-MFN2 driven Mito- SR interactions, altered calcium regulation, cell death signaling and metabolic dysfunction in I/R hearts by cell intrinsic mechanisms in MΦs, and via MΦ-CM cross-talk. We will probe comprehensive mechanisms in cardiac stresses evoked by I/R using murine models, both in the absence and presence of DM. We will employ novel Ager and Diaph1 floxed mice, small molecule antagonists of RAGE-DIAPH1 interaction, state-of-the-art molecular techniques, proteomics, and magnetic resonance spectroscopy to uncover mechanisms of I/R injury in DM hearts.Proposed studies in this project will identify novel mechanism MΦ specific mechanism, as well as MΦ-CM cross talk mechanisms by which RAGE-DIAPH1 modulates I/R injury in hearts, particularly in DM hearts. Identification of these mechanisms, along with testing of novel small molecules that block RAGE/DIAPH1 interaction, will pave the way for therapeutic interventions to protect DM hearts from I/R injury. Project 1 will work closely with Projects 2 and 3 and the two Cores to achieve these goals.
项目概述:项目1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ravichandran Ramasamy其他文献

Ravichandran Ramasamy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ravichandran Ramasamy', 18)}}的其他基金

Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications
靶向 RAGE/DIAPH1:糖尿病并发症的新治疗策略
  • 批准号:
    10197120
  • 财政年份:
    2020
  • 资助金额:
    $ 56.36万
  • 项目类别:
Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications
靶向 RAGE/DIAPH1:糖尿病并发症的新治疗策略
  • 批准号:
    10368080
  • 财政年份:
    2020
  • 资助金额:
    $ 56.36万
  • 项目类别:
Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications
靶向 RAGE/DIAPH1:糖尿病并发症的新治疗策略
  • 批准号:
    10596466
  • 财政年份:
    2020
  • 资助金额:
    $ 56.36万
  • 项目类别:
Targeting RAGE/DIAPH1: Novel Therapeutic Strategy for Diabetic Complications
靶向 RAGE/DIAPH1:糖尿病并发症的新治疗策略
  • 批准号:
    10055037
  • 财政年份:
    2020
  • 资助金额:
    $ 56.36万
  • 项目类别:
Core 2: Mouse, Cell and Protein Support, Data Management and Biostatistics Core
核心 2:小鼠、细胞和蛋白质支持、数据管理和生物统计学核心
  • 批准号:
    10191020
  • 财政年份:
    2019
  • 资助金额:
    $ 56.36万
  • 项目类别:
Core 2: Mouse, Cell and Protein Support, Data Management and Biostatistics Core
核心 2:小鼠、细胞和蛋白质支持、数据管理和生物统计学核心
  • 批准号:
    10642706
  • 财政年份:
    2019
  • 资助金额:
    $ 56.36万
  • 项目类别:
Core 2: Mouse, Cell and Protein Support, Data Management and Biostatistics Core
核心 2:小鼠、细胞和蛋白质支持、数据管理和生物统计学核心
  • 批准号:
    10407556
  • 财政年份:
    2019
  • 资助金额:
    $ 56.36万
  • 项目类别:
Project 1:Diabetes, RAGE/DIAPH1 and Myocardial Infarction
项目1:糖尿病、RAGE/DIAPH1与心肌梗塞
  • 批准号:
    10642708
  • 财政年份:
    2019
  • 资助金额:
    $ 56.36万
  • 项目类别:
Project 1:Diabetes, RAGE/DIAPH1 and Myocardial Infarction
项目1:糖尿病、RAGE/DIAPH1与心肌梗死
  • 批准号:
    10407557
  • 财政年份:
    2019
  • 资助金额:
    $ 56.36万
  • 项目类别:
RAGE/mDia1, Macrophage Trafficking and Inflammation in High Fat Feeding
RAGE/mDia1、高脂肪喂养中的巨噬细胞运输和炎症
  • 批准号:
    9906204
  • 财政年份:
    2016
  • 资助金额:
    $ 56.36万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 56.36万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 56.36万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了